There is “substantial reason to believe” that Rep. Chris Collins, R-N.Y., violated ethics standards and federal laws through his actions with biotech firm Innate Immunotherapeutics, a company with which he is invested, the Office of Congressional Ethics announced Thursday.
The report disclosed that in addition to meeting with researchers to help Innate, Collins also disclosed nonpublic information regarding purchasing Innate stock with investors. As a result, Collins could face ethics sanctions or potential criminal prosecution.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.